Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vtv Theraptcs Cl A (VTVT)

Vtv Theraptcs Cl A (VTVT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,492
  • Shares Outstanding, K 90,037
  • Annual Sales, $ 4,010 K
  • Annual Income, $ -12,990 K
  • 60-Month Beta -1.41
  • Price/Sales 16.82
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade VTVT with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.21
  • Most Recent Earnings -0.10 on 05/12/22
  • Next Earnings Date 08/03/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.01
  • Growth Rate Est. (year over year) -900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4533 +65.37%
on 05/25/22
0.9300 -19.40%
on 06/01/22
+0.2430 (+47.97%)
since 05/24/22
3-Month
0.3820 +96.23%
on 05/19/22
0.9300 -19.40%
on 06/01/22
+0.0235 (+3.24%)
since 03/24/22
52-Week
0.3820 +96.23%
on 05/19/22
2.4700 -69.65%
on 06/25/21
-1.6304 (-68.50%)
since 06/24/21

Most Recent Stories

More News
vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

Results confirmed TTP399 improves glycemia without increasing hypoglycemia and suggest a protective effect of TTP399 against DKA in individuals with T1D...

VTVT : 0.7496 (+0.19%)
vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare

HIGH POINT, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million...

VTVT : 0.7496 (+0.19%)
vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March...

VTVT : 0.7496 (+0.19%)
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA

The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.

REGN : 612.49 (+0.84%)
SNY : 53.42 (+5.95%)
ATHX : 0.2548 (-7.35%)
VTVT : 0.7496 (+0.19%)
vTv Therapeutics Shares Updated Corporate Presentation

HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to...

VTVT : 0.7496 (+0.19%)
Intellia (NTLA) Inks Deal With Kyverna for Autoimmune Diseases

Intellia (NTLA) inks a licensing and collaboration deal with Kyverna Therapeutics for developing an allogeneic CAR T-cell therapy for autoimmune diseases.

REGN : 612.49 (+0.84%)
ICPT : 13.56 (+0.22%)
VTVT : 0.7496 (+0.19%)
NTLA : 53.41 (+5.22%)
Genprex's (GNPX) Lead Cancer Drug Gets Second Fast Track Tag

The FDA bestows a Fast Track designation to Genprex's (GNPX) Reqorsa in combination with Keytruda for treating patients with non-small cell lung cancer. This is the second Fast Track tag for Reqorsa.

AZN : 66.90 (+3.80%)
MRK : 93.13 (+1.23%)
VTVT : 0.7496 (+0.19%)
GNPX : 1.4000 (+2.94%)
Apellis (APLS) Up More Than 40% in Past 3 Months: Here's Why

Approval of Apellis' (APLS) Empaveli for treating paroxysmal nocturnal hemoglobinuria lends a significant boost to the company's growth prospects. The drug's label expansion studies also hold promise.

AZN : 66.90 (+3.80%)
SRPT : 75.22 (+4.73%)
VTVT : 0.7496 (+0.19%)
APLS : 46.26 (-1.57%)
Kodiak Sciences (KOD) Focuses on Developing Eye Candidate KSI-301

Kodiak Sciences (KOD) progresses well with the development of its lead candidate, KSI-301, for treating various retinal vascular diseases. Stiff competition in the target market remains a woe.

SRPT : 75.22 (+4.73%)
VTVT : 0.7496 (+0.19%)
KNSA : 10.30 (-3.56%)
KOD : 9.04 (+0.56%)
Palatin (PTN) Begins Phase III Study For Dry Eye Disease

Palatin (PTN) commences the pivotal phase III study evaluating PL9643 for the treatment of dry eye disease. Top-line data from the same is expected in the second half of 2022.

PTN : 0.3070 (+10.04%)
SRPT : 75.22 (+4.73%)
ALDX : 3.68 (+2.51%)
VTVT : 0.7496 (+0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical...

See More

Key Turning Points

3rd Resistance Point 0.8484
2nd Resistance Point 0.8192
1st Resistance Point 0.7844
Last Price 0.7496
1st Support Level 0.7204
2nd Support Level 0.6912
3rd Support Level 0.6564

See More

52-Week High 2.4700
Fibonacci 61.8% 1.6724
Fibonacci 50% 1.4260
Fibonacci 38.2% 1.1796
Last Price 0.7496
52-Week Low 0.3820

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar